Search clinical trials for: aliskiren /amlodipine/hydrochlorothiazide

Total 1032 results

Novartis

Completed

Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension (ASCENT)

Hypertension

United States
Novartis Pharmaceuticals

Terminated

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People (APOLLO)

Cardiovascular Events

Colombia, India, South Africa, Canada, Spain, Hungary, United States, Germany, Ireland, Argentina, Philippines, Brazil, Sweden, Malaysia, Chile, Israel, Czech Republic, Netherlands
Novartis

Completed

Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

Essential Hypertension

Japan
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

Hypertension

Sweden, United States, Peru, Russian Federation, Romania, Mexico, Panama, Spain, Denmark, Italy, Greece, South Africa, Canada, Argentina, Australia, Colombia, Finland, Taiwan
Novartis

Completed

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone

Hypertension

Estonia, France, Iceland, India, Italy, Korea, Republic of, Lithuania, Spain, Venezuela
Novartis

Completed

Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension (ACADEMY)

Stage II Hypertension

Thailand
Daiichi Sankyo, Inc.

Completed

Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension

Essential Hypertension

Italy, Poland, Ukraine, Germany, Spain, Bulgaria, Romania, Denmark, Belgium, Netherlands, Russian Federation, Hungary, Slovakia, Czechia, Latvia
Sir Mortimer B. Davis - Jewish General Hospital
Novartis Pharmaceuticals

Withdrawn

Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries

Hypertension | Diabetes

Canada
Novartis Pharmaceuticals

Completed

Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans (ATLAAST)

Hypertension

United States
Novartis Pharmaceuticals

Terminated

Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension

Hypertension | Ankle Edema

Netherlands
Novartis

Completed

Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine (AWESOME)

Essential Hypertension

Germany
Novartis

Completed

Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension (ACQUIRE)

Hypertension

Switzerland, Italy, Argentina, Germany, Turkey, United States, Ecuador, Guatemala
Swiss Federal Institute of Sport Magglingen

Unknown

Comparison of the Automatized and the Optimized Carbon Monoxid Rebreathing Protocol

Hemoglobins

Switzerland
Daiichi Sankyo, Inc.

Completed

Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension

Essential Hypertension

France, Poland, Ukraine, Belgium, Germany, Spain, Bulgaria, Romania, Denmark, Russian Federation, Netherlands, Austria, Slovakia, Czechia
Novartis

Completed

Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus (ASTRIDE)

Hypertension | Diabetes Mellitus

United States
Novartis

Completed

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

Hypertension

Sweden, United States, Romania, Denmark, Israel, Italy, Germany, Australia, Canada, Latvia, Lithuania, Turkey
Novartis

Completed

Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension

Hypertension

India
Novartis Pharmaceuticals

Terminated

To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy (ARIA)

Non-diabetic Nephropathy

Netherlands
Novartis Pharmaceuticals

Completed

Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

Metabolic Syndrome | Insulin Resistance | Endothelial Dysfunction | High Blood Pressure

United States
Novartis

Completed

Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension (ACCELERATE)

Hypertension

Switzerland, United Kingdom, Venezuela, France, South Africa, Greece, Canada, Costa Rica, Germany, Guatemala
Novartis

Completed

Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension (AMAZING)

Hypertension

Germany
Novartis

Terminated

Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension

Hypertension | Abdominal Obesity

Germany
IlDong Pharmaceutical Co Ltd

Completed

Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients

Essential Hypertension

Korea, Republic of
University of Abuja
Imperial College London; University College Hospital, Ibadan; University of Nairobi and other collaborators

Completed

Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans (Creole)

Hypertension

Nigeria
Yonsei University

Completed

Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome

Hypertension

Korea, Republic of
Novartis

Completed

A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension

Essential Hypertension

Spain, United States, Belgium, Egypt, Germany, Poland, Slovakia, Turkey
Novartis

Completed

An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure

Hypertension

United States, Belgium, Denmark, Finland, Germany, Iceland, India, Switzerland
Novartis

Completed

Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension

Essential Hypertension ( Mild to Moderate)

Romania, Slovakia, Hungary, France
Boehringer Ingelheim

Withdrawn

Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice

Hypertension

Japan
Novartis

Completed

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

Hypertension

Slovakia, Italy, Netherlands, Argentina, Germany, Poland, Czech Republic, Iceland
Novartis Pharmaceuticals

Completed

ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling (ALLMARK)

Hypertension | Left Ventricle Hypertrophy

Spain
Novartis

Completed

Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients With Hypertension Not Adequately Responding to Amlodipine Alone

Hypertension

Sweden, Slovakia, Argentina, Germany, Turkey, Norway, Poland
Novartis

Completed

Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.

Essential Hypertension

Germany, Spain, United States
Novartis

Completed

Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension

Moderate to Severe Hypertension

Russian Federation, Romania, Singapore, Spain, Germany, Philippines
IlDong Pharmaceutical Co Ltd

Completed

Clinical Trial to Compare the Pharmacokinetics of TAH Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers

Healthy

Korea, Republic of
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Hypertension

United States, Belgium, Hungary, Turkey, Guatemala, Slovakia, Germany, Puerto Rico, Poland
UMC Utrecht
Novartis Pharmaceuticals

Completed

Treatment of Adiposity Related hypErTension (TARGET) (TARGET)

Hypertension | Metabolic Syndrome | Abdominal Obesity

Netherlands
Shanghai Jiao Tong University School of Medicine

Recruiting

Efficacy and Safety of a Single-pill Fixed Combination of Sufficient Losartan/Hydrochlorothiazide in Chinese Hypertensive Patients

Hypertension

China
Novartis Pharmaceuticals

Completed

Effect of Light Meal on Pharmacokinetic and Pharmacodynamics of Aliskiren in Patients With Mild to Moderate Hypertension

Hypertension

India
Novartis

Completed

SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction

Hypertension

Japan
University of Campania "Luigi Vanvitelli"
IRCCS San Raffaele

Unknown

RAAS Inhibitor Drugs in Dialysis Patients

Hypertension | End Stage Renal Disease
Novartis

Completed

Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren

Hypertension

United States
University of Pavia

Unknown

Effects of Aliskiren/Amlodipine Versus Amlodipine Monotherapy on Ankle-foot Volume in Hypertensive Patients

Hypertension

Italy
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure

Hypertension

Spain
Novartis Pharmaceuticals
Baker Heart and Diabetes Institute

Completed

Valsartan Intensified Primary Care Reduction of Blood Pressure Study (VIPER-BP)

Hypertension

United States, Australia
Takeda

Completed

Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.

Grade I or II Essential Hypertension

Japan
Boryung Pharmaceutical Co., Ltd

Completed

Drug Interaction Study of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects

Drug-Drug Interaction

Korea, Republic of
Novartis

Completed

Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension (AACESS)

Hypertension

United States
Novartis

Completed

SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension

Hypertension

Japan
Novartis

Completed

A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure

Hypertension

United States, Germany

3

Subscribe